Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling

• Published in: Cancers Vol. 15; no. 2; p. 460
• Main Authors: Cecchi, Fabiola, Rex, Karen, Schmidt, Joanna, Vocke, Cathy D., Lee, Young H., Burkett, Sandra, Baker, Daniel, Damore, Michael A., Coxon, Angela, Burgess, Teresa L., Bottaro, Donald P.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.01.2023; MDPI
• Subjects: Antibodies; Autocrine signalling; Biosynthesis; Brain cancer; c-Met protein; Cancer; Cell activation; Cell survival; Cells; Cholesterol; Clinical trials; Disease control; Drug development; Drug resistance; Endoplasmic reticulum; Experiments; Glioblastoma; Glioblastoma cells; Growth factors; Hepatocyte growth factor; Immunoassay; Kinases; Laboratory animals; Proteins; Regression analysis; Signal transduction; Tumors; United States > US; Thousand Oaks California; glioblastoma; rilotumumab; acquired drug resistance; Met; hepatocyte growth factor

Drug resistance is a long-standing impediment to effective systemic cancer therapy and acquired drug resistance is a growing problem for molecularly-targeted therapeutics that otherwise have shown unprecedented successes in disease control. The hepatocyte growth factor (HGF)/Met receptor pathway sig...